FIELD: pharmaceuticals.
SUBSTANCE: invention relates to a compound of general formula (1), where each of R1, R2 and R3 is given in the claim.
EFFECT: compounds of the invention are inhibitors of cellular anandamide absorption and are intended for treating mental or neurological disorders and inflammation.
6 cl, 11 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| PET BOTTLES WITH A SINGLE-LAYER BARRIER TO CARBON DIOXIDE | 2012 |
|
RU2579595C2 |
| NOVEL DERIVATIVES OF IMIDAZOLIDINE, THEIR PREPARING AND USING AS VLA-4 ANTAGONIST | 2002 |
|
RU2318815C2 |
| DEUTERATED BENZYL BENZENE DERIVATES AND METHODS FOR USE | 2009 |
|
RU2509773C2 |
| FIVE-MEMBERED HETEROCYCLES AS INHIBITORS OF LEUKOCYTE ADHESION AND VLA-4 ANTAGONISTS | 1997 |
|
RU2229296C2 |
| SUBSTITUTED DERIVATIVES OF IMIDAZOLIDINE, METHOD FOR PREPARING AND PHARMACEUTICAL PREPARATION | 1998 |
|
RU2239641C2 |
| BUPRENORPHINE ANALOGUES | 2009 |
|
RU2520222C2 |
| PROTEIN PHOSPHATASE-1 INHIBITORS AND USING THEM | 2009 |
|
RU2527561C2 |
| V1A-RECEPTORS AGONISTS | 2013 |
|
RU2634617C2 |
| SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | 2013 |
|
RU2681209C2 |
| DIPEPTIDE LINKED MEDICINAL AGENTS | 2009 |
|
RU2578591C2 |
